 | • レポートコード：B-MOR-040410 • 出版社/出版日：Mordor Intelligence / 2018年3月 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：医療・バイオ |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、インスリン治療の世界市場について調べ、インスリン治療の世界規模、市場動向、市場環境、製品タイプ別（短期作用インスリン、中期作用インスリン、長期作用インスリン、プレミクスインスリン）分析、薬剤タイプ別（ジェネリック医薬品、ブランド医薬品）分析、疾病タイプ別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・インスリン治療の世界市場インサイト ・インスリン治療の世界市場環境 ・インスリン治療の世界市場動向 ・インスリン治療の世界市場規模 ・インスリン治療の世界市場規模：製品タイプ別（短期作用インスリン、中期作用インスリン、長期作用インスリン、プレミクスインスリン） ・インスリン治療の世界市場規模：薬剤タイプ別（ジェネリック医薬品、ブランド医薬品） ・インスリン治療の世界市場規模：疾病タイプ別 ・インスリン治療の世界市場：地域別市場規模・分析 ・インスリン治療の北米市場規模・予測 ・インスリン治療のアメリカ市場規模・予測 ・インスリン治療のヨーロッパ市場規模・予測 ・インスリン治療のアジア市場規模・予測 ・インスリン治療の日本市場規模・予測 ・インスリン治療の中国市場規模・予測 ・インスリン治療のインド市場規模・予測 ・インスリン治療の韓国市場規模・予測 ・関連企業情報・競争状況 |
The global insulin therapeutics market is expected to register a CAGR of 8.0% during the forecast period, 2018 to 2023. North America dominates the market, due to growing prevalence of diabetes and obesity in the region.
Growing Obesity and Diabetes Prevalence, Especially in Developing Countries
Diabetes ranks among the fast-growing chronic diseases in the United States; currently, diabetes affects more than 29 million people in the country. India is among the top three countries with high incidence of diabetes. The diabetic population in the country increased from 11.9 million in 1980, to 69.1 million in 2015. In India, approximately 100 million people are expected to suffer from diabetes, by 2030. The genetic factor is one of the major reasons for the rapid spread of the disease. Indians are four times more likely to develop the disease in comparison to other regions, such as Europe. The sedentary lifestyles and obesity are the other factors responsible for high prevalence of the disease. India is among the top five countries with people suffering from obesity, with more than 9.8 million obese men, covering about 3.7% of the global population. Thus, increasing prevalence of obesity and diabetes across the globe will surge a huge demand for insulin, which will drive the global market of insulin therapeutics.
Highly Competitive Market – Leading to Increasing Pricing Pressure
Currently, approximately 100 million people around the world need insulin, including all people living with Type 1 diabetes and between 10-25% of people with Type 2 diabetes. Although insulin has been used in the treatment of diabetes for over 90 years, globally, more than half the people who need insulin today still cannot afford and/or access it. The inaccessible treatment will lead to diabetes-related complications, like blindness, amputation, and kidney failure, and, ultimately, premature death. There are many complex issues that affect access to this life-saving medicine, creating inequity and inefficiency in the global insulin market. These issues include the domination of the global insulin market by three multinational manufacturers, import duties affecting the price insulin entering different countries, and mark-ups, taxes, and other charges in the public and private sector supply chains that affect the final patient price, which is likely to impede the growth of the global insulin therapeutics market.
North America to Dominate the Market
North America dominates the global insulin therapeutics market, owing to high prevalence of diabetes in the region because of sedentary lifestyle, and launch of new drugs in the region. Asia-Pacific is expected to grow tremendously during the forecast period, owing to factors, such as high prevalence of obesity, and growing awareness regarding diabetes care in the region.
Key Developments in the Market
• May 2017: Novo Nordisk A/S launched Xultophy 100/3.6 (insulin degludec and liraglutide injection) in the United States.
• December 2017: Merck Co.7 Inc. and Pfizer Inc. received US Food and Drug Administration (FDA) approval for STEGLATROTM (ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, and the fixed-dose combination STEGLUJAN (ertugliflozin and sitagliptin) tablets.
Major Players: ASTRAZENECA, BIOCON, BIOTON S.A., ELI LILLY AND COMPANY, JULPHAR, MERCK & CO., INC., NOVO NORDISK A/S, TEVA PHARMACEUTICAL INDUSTRIES LTD, SANOFI-AVENTIS, AND WOCKHARDT LTD, among others.
Reasons to Purchase this Report
• Current and future global insulin therapeutics market outlook in the developed and emerging markets
• Analysis of various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players
• 3 months analyst support, along with the Market Estimate sheet (in excel)
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.
レポート目次1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Growing Obesity and Diabetes Prevalence Worldwide
6.1.2 Strong R&D investment from Key Players Offering Promising Molecules Increasing the Patient Base
6.1.3 Extensive & Well-established Distribution Network of Insulin Drugs
6.1.4 Biologics Going Off-Patent
6.2 Market Restraints
6.2.1 High Out-of-Pocket and Low Healthcare Expenditure on Diabetes
6.2.2 Highly Competitive Market Leading to Increasing Pricing Pressure
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Product Type
7.1.1 Short-acting Insulin
7.1.2 Intermediate-acting Insulin
7.1.3 Long-acting Insulin
7.1.4 Premixed Insulin
7.2 By Drug Type
7.2.1 Generic Drugs
7.2.2 Branded Drugs
7.3 By Disease Type
7.3.1 Type 1 Diabetes
7.3.2 Type 2 Diabetes
7.4 By Geography
7.4.1 North America
7.4.1.1 United States
7.4.1.2 Canada
7.4.1.3 Mexico
7.4.2 Europe
7.4.2.1 France
7.4.2.2 Germany
7.4.2.3 United Kingdom
7.4.2.4 Italy
7.4.2.5 Spain
7.4.2.6 Rest Of Europe
7.4.3 Asia-Pacific
7.4.3.1 China
7.4.3.2 Japan
7.4.3.3 India
7.4.3.4 Australia & New Zealand
7.4.3.5 South Korea
7.4.3.6 Rest of Asia-Pacific
7.4.4 Middle East & Africa
7.4.4.1 GCC
7.4.4.2 South Africa
7.4.4.3 Rest of the Middle East & Africa
7.4.5 South America
7.4.5.1 Brazil
7.4.5.2 Argentina
7.4.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers & Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 AstraZeneca PLC
9.2 Biocon
9.3 Bioton S.A.
9.4 Eli Lilly and Company
9.5 Julphar
9.6 Merck & Co., Inc.
9.7 Novo Nordisk A/S
9.8 Teva Pharmaceutical Industries Ltd
9.9 Sanofi-Aventis
9.10 Wockhardt Ltd
9.11 Others
10. Future of the Market